Study 37 of 37Semaglutide literatureThe lancet. Diabetes & endocrinologyTop journal2026
Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis.
Not reported in abstract.
Where it sits
this study against the rest of the semaglutide corpus8
Preclinical · this one
23
Observational
0
Open-label
2
Randomised
4
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Semaglutide corpus
DMultimodal Strategies for Obesity Management: Integration and Combination of GLP-1/GIP Therapies, Bariatric Endoscopy, and Metabolic Surgery: A Scoping Reviewbiorxiv-preprint · 2026 · Not reported in abstract.reviewBReal-World Insulin Deintensification and Discontinuation with GLP-1 Incretin Therapies Versus SGLT2 Inhibitors in Type 2 Diabetesbiorxiv-preprint · 2026 · 27.8% discontinued basal insulin with semaglutide vs 22.2% with SGLT2-i at 24 months, sHR 1.26, 95% CI 1.05–1.52, Gray P=0.013HumanBCardiovascular Outcomes of Tirzepatide vs Semaglutide in Obesity Without Type 2 Diabetes: A Matched Cohort Studybiorxiv-preprint · 2026 · HR 0.80; 95% CI 0.69–0.92 for MACE at 12 months.HumanDNeuro-Adverse Events Associated with GLP-1 Receptor Agonists: A Study Based on the FAERS Database and External Validation Using NHANES Databasebiorxiv-preprint · 2026 · ROR 3.94; 95%CI 3.42-4.54 for muscle atrophy with semaglutide.reviewDMapping Models of Tirzepatide Delivery for Obesity Management in Primary Care Settingsbiorxiv-preprint · 2026 · Not reported in abstract.reviewBGlucagon-like peptide-1 receptor agonists and healthcare use in older adults with heart failure and obesitybiorxiv-preprint · 2026 · Adjusted risk ratio for all-cause inpatient utilization was 0.89 (95% CI: 0.84 – 0.93) for HF therapy + GLP-1 RA vs HF therapy.Human